S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Options Trading Plan–Perfect For Beginners (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
The gold catalyst we've waited for (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
The gold catalyst we've waited for (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Options Trading Plan–Perfect For Beginners (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
The gold catalyst we've waited for (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
The gold catalyst we've waited for (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Options Trading Plan–Perfect For Beginners (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
The gold catalyst we've waited for (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
The gold catalyst we've waited for (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Options Trading Plan–Perfect For Beginners (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
The gold catalyst we've waited for (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
The gold catalyst we've waited for (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
TSE:GUD

Knight Therapeutics (GUD) Stock Forecast, Price & News

C$4.42
-0.01 (-0.23%)
(As of 09/25/2023 ET)
Compare
Today's Range
C$4.38
▼
C$4.43
50-Day Range
C$4.38
▼
C$4.93
52-Week Range
C$4.28
▼
C$5.60
Volume
32,890 shs
Average Volume
97,723 shs
Market Capitalization
C$471.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$6.25
ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesSocial Media

Knight Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
41.4% Upside
C$6.25 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
C$115,738 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

See Top Rated MarketRank™ Stocks Here

GUD stock logo

About Knight Therapeutics (TSE:GUD) Stock

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

GUD Price History

GUD Stock News Headlines

September 14, 2023 | theglobeandmail.com
Closing Bell: Knight Therapeutics Inc flat on Thursday (GUD)
August 12, 2023 | markets.businessinsider.com
Knight Therapeutics (KHTRF) Receives a Buy from RBC Capital
September 26, 2023 | Chaikin Analytics (Ad)
Get Your Cash Out of U.S. Banks Immediately
Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.
August 10, 2023 | theglobeandmail.com
Trading For This Specialty Pharma Company is up Following Second Quarter Results
August 10, 2023 | finance.yahoo.com
Knight Therapeutics Reports Second Quarter 2023 Results
August 3, 2023 | finance.yahoo.com
Notice of Knight Therapeutics' Second Quarter 2023 Results Conference Call
June 7, 2023 | theglobeandmail.com
Closing Bell: Knight Therapeutics Inc up on Tuesday (GUD)
June 2, 2023 | finance.yahoo.com
Knight to Present at the Jefferies 2023 Healthcare Conference in New York City
September 26, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
May 31, 2023 | theglobeandmail.com
Closing Bell: Knight Therapeutics Inc down on Wednesday (GUD)
May 26, 2023 | finance.yahoo.com
Samira Sakhia Bought 12% More Shares In Knight Therapeutics
May 26, 2023 | finance.yahoo.com
Samira Sakhia Bought 12% More Shares In Knight Therapeutics \
May 23, 2023 | finance.yahoo.com
Shareholders in Knight Therapeutics (TSE:GUD) are in the red if they invested five years ago
May 8, 2023 | theglobeandmail.com
Closing Bell: Knight Therapeutics Inc down on Monday (GUD)
May 4, 2023 | finance.yahoo.com
Notice of Knight Therapeutics' First Quarter 2023 Results Conference Call
April 28, 2023 | theglobeandmail.com
Closing Bell: Knight Therapeutics Inc down on Friday (GUD)
April 18, 2023 | finance.yahoo.com
Knight to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 10, 2023 | theglobeandmail.com
Closing Bell: Knight Therapeutics Inc up on Monday (GUD)
March 25, 2023 | marketwatch.com
Knight Therapeutics Inc. ranks on The Globe and Mail's fourth-annual Women Lead Here benchmark of executive gender diversity
March 23, 2023 | finance.yahoo.com
Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results
February 28, 2023 | benzinga.com
Knight Therapeutics Stock (OTC:KHTRF), Quotes and News Summary
January 27, 2023 | nypost.com
Spielberg: ‘Dark Knight’ should’ve been Oscars’ first Best Picture blockbuster
January 18, 2023 | msn.com
Wayne Knight Claims Seinfeld 'Obliterated' His Film Career
November 8, 2022 | finance.yahoo.com
Bullish insiders bet CA$2.9m on Knight Therapeutics Inc. (TSE:GUD)
October 11, 2022 | finance.yahoo.com
Knight Therapeutics Inc. (TSE:GUD) most popular amongst individual investors who own 57%, insiders hold 20%
September 23, 2022 | finance.yahoo.com
Knight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing Companies
September 1, 2022 | reuters.com
Knight Therapeutics Inc
See More Headlines
Receive GUD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GUD Company Calendar

Last Earnings
8/10/2023
Today
9/25/2023
Next Earnings (Estimated)
11/09/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Drug Manufacturers—Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
TSE:GUD
CUSIP
N/A
CIK
N/A
Web
www.gud-knight.com
Phone
514-484-4483
Fax
N/A
Employees
698
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$6.25
High Stock Price Forecast
C$6.50
Low Stock Price Forecast
C$6.00
Forecasted Upside/Downside
+41.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
C($0.14)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
-1013.5
Net Income
C$-15,690,000.00
Net Margins
-4.81%
Pretax Margin
N/A
Return on Equity
-1.92%
Return on Assets
-0.84%

Debt

Debt-to-Equity Ratio
9.81
Current Ratio
3.16
Quick Ratio
1.79

Sales & Book Value

Annual Sales
C$326.44 million
Price / Sales
1.45
Cash Flow
C$1.15 per share
Price / Cash Flow
3.85
Book Value
C$7.53 per share
Price / Book
0.59

Miscellaneous

Outstanding Shares
106,770,000
Free Float
N/A
Market Cap
C$471.92 million
Optionable
Not Optionable
Beta
0.48
10 Best Stocks to Own in 2023 Cover
10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Jonathan Ross Goodman B.A. (Age 54)
    BA, L.L.B., LLB, M.B.A., MBA, Exec. Chairman
    Comp: $250.94k
  • Ms. Samira Sakhia BCom (Age 55)
    CA, CPA, MBA, Pres, CEO & Director
    Comp: $674.28k
  • Mr. Arvind Utchanah
    Chief Financial Officer
  • Ms. Amal Khouri B.Sc.
    M.B.A., Chief Bus. Officer
  • Mr. Jeff Martens
    Global VP of Commercial
  • Mr. Stephani Saverio
    VP of Bus. Devel.
  • Mr. Leopoldo Bosano
    Vice-Pres of Manufacturing & Operations
  • Ms. Monica Percario
    Global VP of Scientific Affairs
  • Mr. Henrique Dias
    Global Director of Marketing
  • Ms. Susan Caroline Emblem
    Global VP of HR

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













GUD Stock - Frequently Asked Questions

Should I buy or sell Knight Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GUD shares.
View GUD analyst ratings or view top-rated stocks.

What is Knight Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued 1-year price objectives for Knight Therapeutics' stock. Their GUD share price forecasts range from C$6.00 to C$6.50. On average, they predict the company's share price to reach C$6.25 in the next twelve months. This suggests a possible upside of 41.4% from the stock's current price.
View analysts price targets for GUD or view top-rated stocks among Wall Street analysts.

How have GUD shares performed in 2023?

Knight Therapeutics' stock was trading at C$5.18 at the beginning of the year. Since then, GUD shares have decreased by 14.7% and is now trading at C$4.42.
View the best growth stocks for 2023 here.

When is Knight Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our GUD earnings forecast.

How were Knight Therapeutics' earnings last quarter?

Knight Therapeutics Inc. (TSE:GUD) issued its earnings results on Thursday, August, 10th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by $0.01. The business had revenue of $89.91 million for the quarter, compared to analysts' expectations of $80.15 million. Knight Therapeutics had a negative net margin of 4.81% and a negative trailing twelve-month return on equity of 1.92%.

What other stocks do shareholders of Knight Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Constellation Software (CSU), Bombardier, Inc. Class B (BBD.B), Brookfield Infrastructure Partners (BIP.UN), Enbridge (ENB), Spin Master (TOY), Alimentation Couche-Tard (ATD.B), Chemtrade Logistics Income Fund (CHE.UN), Canadian National Railway (CNR), Dollarama (DOL) and Extendicare (EXE).

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD."

How do I buy shares of Knight Therapeutics?

Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Knight Therapeutics' stock price today?

One share of GUD stock can currently be purchased for approximately C$4.42.

How much money does Knight Therapeutics make?

Knight Therapeutics (TSE:GUD) has a market capitalization of C$471.92 million and generates C$326.44 million in revenue each year. The company earns C$-15,690,000.00 in net income (profit) each year or C($0.14) on an earnings per share basis.

How many employees does Knight Therapeutics have?

The company employs 698 workers across the globe.

How can I contact Knight Therapeutics?

Knight Therapeutics' mailing address is 3400 de Maisonneuve Boulevard West, Suite 1055, Montreal, QC H3Z 3B8, Canada. The official website for the company is www.gud-knight.com. The company can be reached via phone at 514-484-4483.

This page (TSE:GUD) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -